Evidence map›Paper›PMID 42856815›Full record

ArticleFrontiers in nephrology2026

Predictors of renal and patient survival in lupus nephritis: a 28-year single-center cohort study.

Alexandra Vrabie, Bogdan Obrişcă, Bogdan Sorohan, Roxana Jurubiţă, Camelia Achim, Diana Silvia Zilişteanu, Andreea Gabriela Andronesi, Gabriela Lupuşoru, Elena Emanuela Rusu, Raluca Bobeică and 7 more

Abstract read
In one paragraph

Article in Frontiers in nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Alexandra VrabieNephrology Department, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Bogdan ObrişcăNephrology Department, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Bogdan SorohanNephrology Department, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Roxana JurubiţăNephrology Department, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Camelia AchimNephrology Department, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Diana Silvia ZilişteanuNephrology Department, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Andreea Gabriela AndronesiNephrology Department, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Gabriela LupuşoruNephrology Department, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Elena Emanuela RusuNephrology Department, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Raluca BobeicăNephrology Department, Fundeni Clinical Institute, Bucharest, Romania.
Elena Georgia MicuNephrology Department, Fundeni Clinical Institute, Bucharest, Romania.
Sonia BălănicăNephrology Department, Fundeni Clinical Institute, Bucharest, Romania.
Andreea BerechetNephrology Department, Fundeni Clinical Institute, Bucharest, Romania.
Valentin MocanuNephrology Department, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Ştefan LujinschiNephrology Department, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Nicu CaceauneInternal Medicine Department, Fundeni Clinical Institute, Bucharest, Romania.
Gener IsmailNephrology Department, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Despite advances in the understanding and treatment of lupus nephritis (LN), long-term renal and patient outcomes remain suboptimal. Identifying reliable predictors of prognosis and early treatment response is essential for improving risk stratification and guiding management. Methods: We conducted a retrospective cohort study of patients with biopsy-proven LN. Long-term renal and patient survival, renal response at 6 and 12 months, and predictors of a composite outcome (doubling of serum creatinine, end-stage kidney disease [ESKD], or death) were evaluated. Results: A total of 147 patients were included, with a median follow-up of 39.5 months. 10.3% of patients had a doubling of serum creatinine, 11.0% progressed to ESKD, and 6.8% died. Proteinuria <0.7 g/day was achieved by 49.1% and 54.4% of patients at 6 and 12 months, respectively. In multivariate analysis, baseline predictors of the composite outcome included age >50 years, proteinuria ≥3 g/day, and hemoglobin <10 g/dL, while an activity index ≥9 and low baseline C4 levels showed a protective trend. Achieving proteinuria <0.7 g/day at 12 months emerged as the strongest protective factor. A prognostic score demonstrated good discrimination (area under the curve [AUC] 0.82), which improved further with the addition of proteinuria at 12 months (AUC 0.86). Conclusions: In this biopsy-proven LN cohort, early renal response, particularly proteinuria <0.7 g/day at 12 months, was the strongest predictor of long-term renal and patient survival. These findings support a dynamic, response-based approach to prognostication in LN and provide the basis for a clinically applicable prognostic score that requires external validation.

Indexed as

chronic kidney diseaseend stage kidney diseaselupus nephritisprognostic scoresystemic lupus erythematosus

Identifiers

PMID42856815
PMCPMC13649432

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.